Clinical Trial: Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is Daratumumab.

The trial is open at the Dana Farber Cancer Institute, run by Dr. Irene Ghobrial, a myeloma specialist with a focus on precursor conditions. It is also open at Beth Israel Deaconess Medical Center in Boston.

To find all eligible clinical trials, click here:  Study of the CD38 Antibody Daratumumab Clinical Trial